The full study, “MIF‑Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant Across Central Nervous System Disorders,” is available online in Cancer ...
Professor Emmett will showcase data from her OPTIMAL-PSMA 2 investigator-initiated trial of TLX597-Tx ( 177 Lu-DOTA-PSMA), Telix’s novel second generation small molecule candidate being developed to ...
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...
Arbor will also present two posters showcasing novel approaches that support accelerated development of gene editors: one providing high resolution mapping of in vivo genome editing outcomes in the ...
Oral Presentation: Title: Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C Session Date and Time: Thursday, May 14, 3:30 ...
Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be available on the Events page of the ...
Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced four presentations of new preclinical data at the ...
Additional information, including the accepted abstracts, can be accessed on the website of the ASGCT 2026 Annual Meeting. Presentation materials will be made available on the Posters & Publications ...
Dr. Ronald Crystal is a founder, chief scientific advisor, consultant, equity holder and board observer of Lexeo Therapeutics and is an inventor on intellectual property assigned to Weill Cornell ...
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven advanced therapy CDMO and gene editing services partner, today announced presentations at the upcoming American ...
Deep-learning guided optimization of a small molecule-regulated RNA switch for titratable AAV transgene expression.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results